Vimarsana
Biggest News Aggregation in the World

Page 3 - Cell Pouch System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Pouch System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Pouch System Today - Breaking & Trending Today

2023-07-26 | TSX:SVA | Press Release - Vimarsana News

2023-07-26 | TSX:SVA | Press Release

(2023-07-26 | TSX:SVA) Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph.D., MBA, as Chief Business Officer

After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes - Vimarsana News

After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes

The FDA recently approved the first cellular therapy for Type 1 diabetes and others may not be far behind. But experts say challenges still exist to the widespread application of these treatments.

Sernova reports positive interim data for Cell Pouch System - Vimarsana News

Sernova reports positive interim data for Cell Pouch System

Sernova today announced positive interim data from the clinical trial of its Cell Pouch System in patients with type 1 diabetes.

Sernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessions - Sernova (OTC:SEOVF) - Vimarsana News

Sernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessions - Sernova (OTC:SEOVF)

LONDON, Ontario, June 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, will be presenting updated interim data from its

Sernova is significantly undervalued, says Echelon - Vimarsana News

Sernova is significantly undervalued, says Echelon

Echelon Capital Markets analyst Stefan Quenneville continues to beat the drum for Canadian biotech company Sernova in a Thursday report